Tag: Pharma

OAKLAND, Calif., Oct. 19, 2015 (SEND2PRESS NEWSWIRE) -- Council for Vaccine Safety, and A Voice for Choice, in collaboration with community leaders, announce that on October 24, 2015 at 12 noon, protesters will rally at Frank Ogawa Plaza in Oakland, Calif. in solidarity with the Truth, Transparency and Freedom Rally happening on the same day at the CDC in Atlanta, Georgia.

SAN PEDRO, Calif., July 17, 2015 (SEND2PRESS NEWSWIRE) -- Schoenwetter Supplements, LLC is excited to announce the release of an advanced concept formulation of antioxidants, RxQ Antioxidant Complex. Its proprietary antioxidant formula takes into consideration not only adding antioxidants that can rapidly be depleted but is mindful of the necessary other constituents that serve to help recycle some important antioxidant systems that are everywhere present in our bodies.

NEW YORK, N.Y., Feb. 11, 2015 (SEND2PRESS NEWSWIRE) -- Ellen Relkin, of counsel attorney with Weitz and Luxenberg, P.C., has been named to the plaintiffs' steering committee created by judicial order to facilitate lawsuits against the makers of the anticoagulant drug Xarelto, the personal injury and mass tort law firm today announced.

NEW YORK, N.Y., Feb. 11, 2015 (SEND2PRESS NEWSWIRE) -- Ellen Relkin, of counsel attorney with Weitz and Luxenberg, P.C., has been named to the plaintiffs' steering committee created by judicial order to facilitate lawsuits against the makers of the anticoagulant drug Xarelto, the personal injury and mass tort law firm today announced.

PORTLAND, Ore., Nov. 17, 2014 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, announced today that it has received CE mark approval for the recently FDA cleared Comfortear(R) Lacrisolve(TM) Absorbable Punctum Plug. CE mark approval is recognized and associated with safety and performance in multiple countries.

PORTLAND, Ore., Oct. 15, 2014 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, will be exhibiting at the American Academy of Ophthalmology (Booth #4550) in Chicago, Ill., on October 18 - 21.

PLYMOUTH, Minn., Oct. 14, 2014 (SEND2PRESS NEWSWIRE) -- SilkTears, LLC, a privately held, research-based and product-driven biotechnology company, announced today that advances in protein-based excipient technology may allow for the development of artificial tear products that will more closely represent certain characteristics of the natural makeup of the tear film, and may help the significant population of patients suffering from dry eye syndrome.

CLEVELAND, Ohio, July 1, 2014 (SEND2PRESS NEWSWIRE) -- Lakewood College is pleased to announce a new payment plan option that will allow students to graduate from the Pharmacy Technician Certificate Program without going thousands of dollars into debt.

PORTLAND, Ore., June 4, 2014 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., a privately held U.S. biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, announces its FDA approved Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil, is readily available through Bausch + Lomb or your primary wholesaler.

NEW YORK CITY, N.Y., April 9, 2014 (SEND2PRESS NEWSWIRE) -- A Louisiana jury has awarded $9 billion to a New York man who developed bladder cancer after taking Actos, Weitz and Luxenberg announced today. The verdict, issued Monday night, orders Takeda Pharmaceuticals to pay $6 billion in punitive damages, and Eli Lilly to pay $3 billion.

PORTLAND, Ore., April 9, 2014 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, received FDA approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil on March 21, 2013.

HUNTINGTON BEACH, Calif., Nov. 14, 2013 (SEND2PRESS NEWSWIRE) -- SignatureCLL today announced that the first laboratory test ever shown in a clinical trial to improve one year survival rates in cancer is now available to patients with chronic lymphocytic leukemia (also called CLL). The U.S. cancer physician who invented the test and the British scientist who used it to make discoveries in leukemia will offer the test under the trade name SignatuRx(TM) through their own, newly-formed laboratory company.

PORTLAND, Ore., Nov. 8, 2013 (SEND2PRESS NEWSWIRE) -- Leading biopharmaceutical company Paragon BioTeck, Inc. announced today that it plans to launch its new line of products, known as Ilast(R), at the Annual American Academy of Ophthalmology meeting in New Orleans. Paragon signed an exclusive distribution agreement with Horus Pharma to supply Ilast(R) ocular care products in the U.S. last month, and the company is excited to release these products to ophthalmology professionals.

CHICAGO, Ill., Nov. 6, 2013 (SEND2PRESS NEWSWIRE) -- Natural supplement company Nutronics Labs released a statement today encouraging deer antler spray consumers to do thorough product research before buying health supplements online. Nutronics Labs is the leading manufacturer of deer antler spray and boasts the world's strongest supplements available - but as the popularity of their products continues to grow, they have seen hundreds of imitation products flood the market recently.

MADISON, N.J. and TIGARD, Ore. (SEND2PRESS NEWSWIRE) -- Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon's phenylephrine in the United States on an exclusive basis beginning this month.

ATLANTA, Ga. /Florida Newswire/ -- CMI's Mike Mabey, vice president, client solutions, and Jarod Ricci, senior manager, market analytics, Pfizer (NYSE:PFE), will present 'Using Information-Seeking Behavior to Drive Segment-Specific Communication Strategies' at the 2012 PMRG (Pharmaceutical Marketing Research Group) Annual National Conference.